The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Pozen Inc.  (POZN) Trade Now »     Rate POZN  -  Discuss POZN  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
81.5%
Top:
100.0%
Rate POZN:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

POZN: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

Zacks Analyst Blog Highlights: Pozen, Sanofi-Aventis, Bristol-Myers, AstraZeneca and ADC Telecommunications Inc. – Press Releases
Logo1
38%

For Immediate Release

Chicago, IL – November 23, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pozen (POZN), Sanofi-Aventis (SNY), Bristol-Myers (BMY), AstraZeneca (AZN) and ADC Telecommunications Inc. (ADCT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

<><>Pozen...
By  StraightStocks   (-6.57%  risk: moderate)  11/23/09 Comment


Pozen Initiates New Phase III – Analyst Blog
Logo1
38%

This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study.

The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 m...
By  StraightStocks   (-6.57%  risk: moderate)  11/20/09 Comment


Pozen Files For Approval of Vimovo
28%
By 2013 Pozen (POZN) should be posting revenues near $200 million, with high profitability.
By  reity   (-33.13%  risk: aggressive)  06/30/09 Comment


Pozen Files For Approval of Vimovo
By 2013 Pozen (POZN) should be posting revenues near $200 million, with high profitability.
By  Zacks.com   (-13.23%  risk: moderate)  06/30/09 Comment


Morning Movers 1/29: Allstate (ALL) Lower Following Results, Credit Downgrade; Sepracor (SEPR) Up On Results/Guidance

StreetInsider.com Morning Movers:


<>POZEN Inc. (NASDAQ: POZN) 30% HIGHER; Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint

Lloyds Banking Group plc (NYSE: LYG) 25% LOWER; UK banks continue to see extreme volitility.

DryShips, Inc. (Nasdaq: DRYS) 23% LOWER; filed to offer up to $500 million in common shares.

Innovative Solutions and Support, Inc. (Nasdaq: ISSC) 24% LOWER; reports Q1 EPS of $0.11, 8 cents better than the analyst estimate of $0.03. Revenue for the quarter was $10.6 million, versus the consensus of $9.47 million. Innovative Sol...
By  Street Insider   (+9.67%  risk: moderate)  01/29/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
PFE Pfizer Inc
IBM International Business Machines Corp
F Ford Motor Company
BAC Bank of America Corp
ETFC E*Trade Financial Corp
EBAY eBay Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on POZN

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Pozen Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch